Login
MENU
A recent study led by Dr. Andrea Edlow from Massachusetts General Hospital underscores the significance of administering the respiratory syncytial virus (RSV) vaccine to pregnant women as a protective measure for newborns and infants against the virus, a leading cause of infant hospitalization in the United States. However, the research highlights that the timing of the vaccine during pregnancy plays a critical role in optimizing the transfer of maternal antibodies to the newborn.
Dr. Edlow, a maternal-fetal medicine specialist, and her team sought to address uncertainties surrounding the optimal timing for administering the RSV vaccine within the approved gestational age window. The vaccine was initially studied over a broader gestational period, but its final approval limits administration to weeks 32-36 of pregnancy. This study aims to provide clarity on the most effective weeks for vaccination to ensure maximum antibody transfer.
The research team analyzed RSV antibodies in umbilical cord blood at delivery and assessed antibody levels in the blood of infants at two months old. The study included 124 women vaccinated against RSV during weeks 32-36 of their pregnancy and receiving care at Massachusetts General Hospital or Mount Sinai Health System in New York City. By comparison, the team also assessed antibodies in 20 unvaccinated mothers.
Results indicated that vaccinating pregnant women at least five weeks before delivery facilitated the most efficient transplacental transfer of antibodies to the newborn, outperforming vaccinations given closer to the delivery date. The vaccinated mothers exhibited significantly higher and more prolonged maternal and cord blood RSV antibody levels than unvaccinated counterparts.
Dr. Edlow emphasized the importance of this finding in guiding healthcare providers to advise patients effectively on RSV vaccination timing during pregnancy. The study suggests that earlier vaccination within the approved window enhances antibody transfer to newborns and may inform the timing of administering the RSV monoclonal antibody, Nirsevimab, to newborns.
However, more research is necessary to determine the minimum antibody transfer required to protect infants from RSV adequately. The study highlights the need for understanding additional protection through breastmilk in RSV-vaccinated mothers. While this study is pivotal in understanding antibody transfer, larger-scale research is needed to evaluate the extent of protection conferred to infants aged two to six months.
